| Literature DB >> 35198423 |
Abstract
In the era of evidence-based medicine, real-world evidence (RWE) studies have opened avenues to utilize real-world data (RWD) effectively for improving clinical decision-making. However, the transformation of RWD into a meaningful RWE can only be achieved when the researcher asks the right clinical question, selects the right RWD source for variables of interest, uses the right study design, and applies the right statistical analysis. The generated RWE needs to have internal as well as external validity to be actionable. The "fit-for-purpose" observational study designs include descriptive, case-control, cross-sectional, and cohort. This article focuses on the advantages and disadvantages including the inherent bias of each study design. The RWE study decision guide has also been provided to aid the selection of appropriate study designs. Copyright:Entities:
Keywords: Bias; observational; real-world evidence; study designs
Year: 2022 PMID: 35198423 PMCID: PMC8815667 DOI: 10.4103/picr.picr_217_21
Source DB: PubMed Journal: Perspect Clin Res ISSN: 2229-3485
Figure 1Classification of real-world evidence study designs; R – retrospective, P – prospective
The design and analysis time frame (relative to the study start or index date) of different types of real-world evidence studies
| Retrospective | Present | Prospective |
|---|---|---|
| Noninterventional case-control study | Cross-sectional study | Noninterventional cohort study with primary data |
| Noninterventional cohort study with secondary data | Registry | |
| Administrative or claims database study | ||
| Electronic health record study |
Figure 2Design of case-control study
Bias in case–control studies
| Type of Bias | Description of Bias |
|---|---|
| Volunteer bias or “healthy volunteer” effect | Significant differences in characteristics and behavior of study volunteers from those of nonvolunteers |
| Prevalence or incidence bias | Missing the subjects who experienced the outcome/exposure for a short duration or a fatal episode remotely in the past |
| Membership bias or “healthy worker” or “healthy migrant” effect | A specific group of people, for example, employed or migrant population, may systematically differ in quality of health from that of the general population; this bias can be controlled by taking controls from the same worker or migrant population |
| Diagnostic/exposure suspicion bias | Information about a subject’s disease status, such as the thromboembolic episode in a woman, influences both the intensity and the outcome of a search for exposure to a putative cause, such as the use of contraceptive pills |
| Recall bias | The cases may have better recall/memory of any possible exposure that could have caused their illness than the controls |
| Family information bias | A new case triggers the flow of information about exposures and illnesses within a family, for example, a rare familial condition that is never mentioned until a family member begins to demonstrate some of the same symptoms |
Figure 3Concurrent and nonconcurrent cohort study design. Adapted from Johnson 2018[3]
Bias in cohort studies
| Type of Bias | Description of Bias |
|---|---|
| Selection bias | A systematic error in creating intervention groups, causing them to differ with respect to measured or unmeasured baseline characteristics, and ultimately prognosis |
| Adjustment for causal intermediates | Adjusting for variables on the causal pathway between treatment and outcome can result in biased estimation of both the total effect of treatment and the direct effect that is not mediated through the adjustment variables |
| Immortal person-time bias | Occur whenever information assessed during follow-up is used to determine a patient’s inclusion or exclusion in the study or treatment group assignmentFor example, when assessing a new drug vs. an old comparator drug, some cohort studies first identify all patients receiving the new drug to maximize the size of this group, and then identify patients receiving the old comparator drug who never receive the new drug, beginning follow-up at the initiation of the relevant treatment for each group [ |
| Depletion of susceptibles or “survivorship bias” | In the Nurses’ Health study, prevalent users of HRT were followed for outcomes and compared with nonusers. Because the HRT group included many patients who had been on treatment for several years, it effectively excluded cardiovascular events occurring shortly after therapy initiation, leaving a cohort of hormone users that were less susceptible to the outcome |
| Reverse causation | When an apparent association between treatment and outcome is because outcome status influences treatment choice, rather than treatment impacting the outcome. |
HRT=Hormone therapy
Real-world evidence study decision guide
| What is your research question? |
| What is the research area of interest? |
| Disease |
| Drug/device |
| Other |
| What is the setting of study conduct? |
| Routine practice |
| Altering of routine practice |
| What are the outcomes of interest? |
| Are the data of interest recorded in routine practice? |
| Primary data collection and need for randomization |
| Secondary data analysis |
| Hybrid |
| What is the directionality of data review and analysis? |
| Retrospective |
| Prospective |
| Hybrid |
| What is the appropriate RWE study design? |
| Case–control |
| Cohort |
| Cross-sectional |
| Pragmatic trial |
| RWE study question – PECO or PICO |
| Population |
| Exposure/intervention |
| Comparison |
| Outcome |
Modified from the RWE Framework flow diagram developed by Xia et al. 2019. RWE=Real-world evidence, PECO=Population, Exposure, Comparator, Outcome, PICO=Population, Intervention, Comparator, Outcome